A modified version of the Simple Biliary Atresia Scoring System (SBASS) offers a noninvasive way for doctors to make a biliary atresia diagnosis, differentiating…
News
A peer-supported telemedicine program in the U.S. significantly increased the likelihood that hepatitis C patients in rural communities would start treatment — and ultimately…
CHOLANGITIS
NewsPBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union (EU), with an earlier decision…
CHOLESTASIS
NewsStudy: New ABCB4 mutations tied to different ages of PFIC3 onset
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…
FATTY LIVER DISEASE
NewsNew names given nonalcoholic fatty liver diseases fit children: Study
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
ALAGILLE SYNDROME
NewsVascular health checks, kidney tests urged for Alagille patients: Review
Kidney and blood vessel problems are common in people with Alagille syndrome, and while these often cause few to no symptoms, they can be…
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…
CHOLESTASIS
NewsBiomarkers of inflammation could help identify ICP, study finds
Women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, have significantly higher scores of two whole-body inflammation biomarkers than women…
FATTY LIVER DISEASE
NewsSemaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
BILIARY ATRESIA
NewsMaralixibat reduces itch in children with biliary atresia: Case series
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
Recent Posts
- FDA OKs linerixibat, now Lynavoy, as first US treatment for itch in PBC
- $24M US grant to back global team working toward hepatitis B cure
- MRI biomarker may predict PSC liver complications: Study
- Vitamins play a key role in liver health, so monitoring your levels is crucial
- First results on maralixibat for rare cholestatic itch due by year’s end